At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
Omega 3 pentaenoic acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacodynamic Effects of a Free-fatty Acid Formulation of Omega-3 Pentaenoic Acid to ENHANCE Efficacy in Adults With Hypertriglyceridemia: The ENHANCE-IT Trial
In Brief
A Phase 2 clinical trial evaluating Omega 3 pentaenoic acid and icosapent ethyl for Hypertriglyceridemia. Completed, enrolled 100 participants across 8 sites.
Detailed Summary
Pharmacodynamic effects of MAT9001 compared to Vascepa in adults with hypertriglyceridemia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertriglyceridemia
CountriesUnited States
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartJun 2020
Primary CompletionNov 2020
Study CompletionJan 2021
TodayJul 2026
First PostedNov 26, 2019
Enrollment StartJun 3, 2020
Primary CompletionNov 27, 2020
Study CompletionJan 18, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.6 years ago
Interventions
Omega 3 pentaenoic aciddrug
Encapsulated omega-3 pentaenoic acid
icosapent ethyldrug
Encapsulated omega-3 acid ethyl esters